# Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept

> **NCT03312855** · PHASE2 · COMPLETED · sponsor: **Deutsches Herzzentrum Muenchen** · enrollment: 334 (actual)

## Conditions studied

- Stable Coronary Artery Disease

## Interventions

- **DRUG:** Revacept 80 mg
- **DRUG:** Revacept 160 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03312855
- **Lead sponsor:** Deutsches Herzzentrum Muenchen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-03-26
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2020-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312855, "Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03312855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*